Goodwill and Other Intangibles - Narrative (Details) $ in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	$ 20,269		$ 20,269	$ 22,933
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]					Cost of sales
IPR&D impairment charges			$ 1,700
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]			Research and development
Contingent consideration liability, changes in estimated fair value			$ (146)	57
Amortization expense for intangible assets			2,100	1,600	$ 1,800
Estimated aggregate amortization expense, 2023	1,800		1,800
Estimated aggregate amortization expense, 2024	1,700		1,700
Estimated aggregate amortization expense, 2025	1,600		1,600
Estimated aggregate amortization expense, 2026	1,500		1,500
Estimated aggregate amortization expense, 2027	1,300		1,300
IPR&D
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	7,661		7,661	9,281
Zerbaxa
Intangible Assets Excluding Goodwill [Line Items]
Intangible asset impairment charge related to marketed product					1,600
Inventory write-down					120
Animal Health
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	4,600		4,600
Adempas | Licenses and other
Intangible Assets Excluding Goodwill [Line Items]
Intangible assets	633		633
COVID-19
Intangible Assets Excluding Goodwill [Line Items]
IPR&D impairment charges					90
Contingent consideration liability, changes in estimated fair value					$ (45)
sotatercept | IPR&D
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	6,400		6,400
nemtabrutinib | IPR&D
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	418		418
IPR&D impairment charges	780	$ 807	1,600	$ 275
nemtabrutinib | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow | Fair Value, Measurements, Recurring
Intangible Assets Excluding Goodwill [Line Items]
Discount rate				0.085
gefapixant | IPR&D
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	832		832
Products and product rights
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	6,810		6,810	$ 7,895
Products and product rights | Reblozyl
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	3,500		3,500
Products and product rights | Zerbaxa
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	406		406
Products and product rights | Sivextro
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	122		122
Products and product rights | Gardasil/Gardasil 9
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	120		120
Products and product rights | Bridion
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	97		97
Products and product rights | Animal Health
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	2,300		2,300
Trade names
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	2,244		2,244	2,389
Trade names | Animal Health
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	2,200		2,200
License
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	3,554		3,554	$ 3,368
License | Lynparza
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	1,600		1,600
License | Lenvima
Intangible Assets Excluding Goodwill [Line Items]
Other intangibles, net	$ 814		814
License | Derazantinib
Intangible Assets Excluding Goodwill [Line Items]
Intangible asset impairment			$ 80